Healthy volunteers help map new drug's brain activity
NCT ID NCT05470101
First seen Sep 30, 2025 · Last updated Jun 11, 2026 · Updated 36 times
Summary
This early-stage study tested a single dose of the experimental drug ITI-333 in 12 healthy adults aged 18-45. Researchers used PET scans to see how much of the drug reached and attached to a specific brain receptor (5-HT2A). The main goals were to measure receptor binding, drug levels in the blood, and safety. This study does not treat any disease but helps understand how the drug works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Site 1
St Louis, Missouri, 63110, United States
-
Clinical Site 2
Creve Coeur, Missouri, 63141, United States
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.